Volume 27, Issue 4 - Patient-reported outcomes

My First Medical Writing

Authors: Evguenia Alechine, Matías Rey-Carrizo

Abstract

References

1. FDA News Release. FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. 2018 [cited 2018 Sep 19]. Available from Available from: https://www.fda.gov/ newsevents/newsroom/pressannouncements/ucm611046.htm.
2. Schultes RE, Klein WM, Plowman T, Lockwood TE. Cannabis: an example of taxonomic neglect. Bot Mus Lealf Harv Univ. 1974;23:337–67.
3. Russo E. Cannabis for migraine treatment: the once and future prescription? An historical and scientific review. Pain. 1998;76(1-2):3–8.
4. Ben Amar M. Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol 2006;105(1-2):1–25.
5. Zuardi AW. History of cannabis as a medicine: a review. Rev Bras Psiquiatr. 2006;28(2):153–7.
6. Gaoni Y, Mechoulam R. Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish. J Am Chem Soc. 1964;86(8):1646–7.
7. Devane WA, Dysarz FA, Johnson RM, Melvin S, Howlett C. Determination and Characterization of a Cannabinoid Receptor in Rat Brain. Mol Pharmacol. 1988;34(5):605–13.
8. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61–5.
9. Devane WA, Hanuš L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor. Science. 1992;258(10):1946–9.
10. Elder JJ, Knoderer HM. Characterization of Dronabinol Usage in a Pediatric Oncology Population. J Pediatr Pharmacol Ther. 2015;20(6):462–7.
11. Pergolizzi JV, Taylor R, LeQuang JA, Zampogna G, Raffa RB. Concise review of the management of iatrogenic emesis using cannabinoids: emphasis on nabilone for chemotherapy-induced nausea and vomiting. Cancer Chemother Pharmacol. 2017;79(3):467–77.
12. Nielsen S, Germanos R, Weier M, Pollard J, Degenhardt L, Hall W, et al. The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews. Curr Neurol Neurosci Rep. 2018;18(8).
13. Syed YY, McKeage K, Scott LJ. Delta-9- Tetrahydrocannabinol/Cannabidiol (Sativex®): A Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis. Drugs. 2014;74(5):563–78.
14. Kalant H. Medical use of cannabis: History and current status. Pain Res Manage. 2011;6(2):80–91.
15. Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, et al. A Random ized, Placebo-Controlled, Crossover Trial of Cannabis Cigarettes in Neuropathic Pain. J Pain. 2008;9(6):506–21.
16. Borgelt LM, Franson KL, Nussbaum AM, Wang GS. The Pharmacologic and Clinical Effects of Medical Cannabis. Pharmaco - therapy. 2013;33(2):195–209.17.
17. Scuderi C, De Filipis D, Iuvone T, Blasio A, Steardo A, Esposito G. Cannabidiol in Medicine: A Review of its Therapeutic Potential in CNS Disorders. Phytother Res. 2009;23:597–602.
18. Devinsky O, Cross JH, FRCPCH, Laux L, Marsh E, Miller I, Nabbout R, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med. 2017;376(21):2011–20.
19. Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085–96.
20. Rosemergy I, Adler J, Psirides A. Cannabidiol oil in the treatment of super refractory status epilepticus. A case report. Seizure. 2016;35:56–8.
21. Shannon S, Opila-Lehman J. Cannabidiol Oil for Decreasing Addictive Use of Marijuana: A Case Report. Integr Med. 2015;14(6):31–5.
22. Chelliah MP, Zinn Z, Khuu P, Teng JMC. Self-initiated use of topical cannabidiol oil for epidermolysis bullosa. Pediatr Dermatol. 2018;35(4):e224–7.
23. Shannon S, Opila-Lehman J. Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report. Perm J. 2016;20(4):108–11.